百日咳重现下MRBp感染的治疗、防控及面临的挑战  

Treatment,Prevention and Challenges of MRBp Infection in the Resurgence of Pertussis

作　　者：薛达 王增国 蒋恺憧[3] 汤舒越 XUE Da;WANG Zengguo;JIANG Kaichong;TANG Shuyue(Shaanxi University of Chinese Medicine,Shaanxi Xianyang 712046,China;Department of Clinical Laboratory,Xi’an Children’s Hospital,Xi’an 710002,China;Institute of Pediatric Diseases,Xi’an Children’s Hospital,Xi’an 710002,China)

机构地区：[1]陕西中医药大学,陕西咸阳712046 [2]西安市儿童医院检验科,西安710002 [3]西安市儿童医院儿科疾病研究所,西安710002

出　　处：《现代检验医学杂志》2024年第4期1-4,22,共5页Journal of Modern Laboratory Medicine

基　　金：国家自然科学基金委员会(8217081223)。

摘　　要：百日咳(whooping cough)是由百日咳鲍特菌(Bordetella pertussis,Bp)感染,通过空气传播的急性呼吸道传染病。大环内酯类抗生素(Macrolides antibiotics)一直是治疗百日咳的首选药物。但自从国内首次报道耐大环内酯类百日咳鲍特菌(Macrolide-resistant Bordetella pertussis,MRBp)后,近年来我国出现了MRBp的广泛流行。尤其近期全球百日咳重现,深入了解MRBp流性特征、诊疗、防控进展及面临的挑战尤为重要。Whooping cough,caused by Bordetella pertussis(Bp)infection,is an acute respiratory infectious disease in children transmitted through the air.Macrolide antibiotics have long been the first-line treatment for whooping cough.However,in recent years,macrolide-resistant Bordetella pertussis(MRBp)has been rarely reported outside China.The high prevalence of MRBp in China adds to the global challenge of whooping cough resurgence.The research firstly reports the emergence of clinical MRBp strains in China and has conducted extensive research in this field.This paper focuses on discussing the progress and challenges in the diagnosis,treatment and prevention of MRBp based on historical and recent studies.

关 键 词：百日咳 百日咳鲍特菌 耐大环内酯类百日咳鲍特菌 诊疗 防控 

分 类 号：R516.6[医药卫生—内科学] R446.5[医药卫生—临床医学]